Notícias e Atividades da Rapport Therapeutics

Rapport Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Rapport Therapeutics é uma empresa listada sob o símbolo RAPP (US).

Fusão, aquisição e financiamento envolvendo Rapport Therapeutics.

• Rapport Therapeutics acaba de anunciar uma arrecadação de fundos de 154 milhões de dólares. (publicado em 11 de junho de 2024).

Veja o organograma con seus 42 executivos principais

Biografias mais buscadas da Rapport Therapeutics

• Abraham Ceesay, Chief Executive Officer
• Wendy Young, Director
• Paul Silva, Director

Recentes movimentos de executivos em Rapport Therapeutics

• Irena Webster, ingressou na Companhia como Senior Vice President, Head of Development Operations  (Notícia publicada em 6 de maio de 2026).

Criar um alerta
para seguir os movimentos de executivos da Rapport Therapeutics.

Rapport Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Rapport Therapeutics

• Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference » Rapport Therapeutics, Inc.
• Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update » Rapport Therapeutics, Inc.
• Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting » Rapport Therapeutics, Inc.
• Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting » Rapport Therapeutics, Inc.
• Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update » Rapport Therapeutics, Inc.
• Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China » Rapport Therapeutics, Inc.
• Rapport Therapeutics to Participate in Upcoming Investor Conferences » Rapport Therapeutics, Inc.
• Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline » Rapport Therapeutics, Inc.
• Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures » Rapport Therapeutics, Inc.
• Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference » Rapport Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Rapport Therapeutics

• Rapport Therapeutics na Wikipedia, Google News e Yahoo Finance
• Rapport Therapeutics na LinkedIn, X (Twitter) e YouTube